Related Experiment Video
Updated: Nov 22, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Long-Term Safety and Efficacy of Percutaneous Left Atrial Appendage Closure with the LAmbre Device
Guangji Wang1,2,3, Bin Kong1,2,3, Yu Liu1,2,3
1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Insights
Left atrial appendage closure (LAAC) with the LAmbre device is safe and effective for preventing stroke in nonvalvular atrial fibrillation (AF) patients. Long-term follow-up confirms high procedural success and low complication rates.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Devices
Background:
- Nonvalvular atrial fibrillation (AF) increases stroke risk.
- Left atrial appendage closure (LAAC) is an alternative to anticoagulation.
- The LAmbre device is used for percutaneous LAAC.
Purpose of the Study:
- To evaluate the long-term safety and efficacy of the LAmbre device for LAAC.
- To assess stroke prevention in patients with nonvalvular AF undergoing LAAC.
Main Methods:
- Analysis of 56 patient records undergoing LAmbre device LAAC.
- Data collection on procedural success, safety, and long-term outcomes.
- Perioperative and long-term follow-up assessment.
Main Results:
- Successful LAAC occlusion in all 56 patients.
- No serious residual leak or pericardial effusion observed.
- At mean 37.8 months follow-up: 7.1% death, 3.6% stroke, 3.6% device-related thrombus; no severe residual leak or systemic embolism.
Conclusions:
- LAAC with the LAmbre device demonstrates high procedural success.
- The LAmbre device effectively prevents AF-related stroke.
- Further large-scale trials are recommended to confirm findings.
Background:
Left atrial appendage closure (LAAC) using the LAmbre device has been associated with prevention of stroke in patients with nonvalvular atrial fibrillation (AF). Here, we interrogated the long-term safety and efficacy of using the LAmbre device in percutaneous LAAC.
Methods:
We analyzed 56 records of patients with nonvalvular AF undergoing LAAC procedures with the LAmbre device. We collected and analyzed the data to define the safety and efficacy of the LAmbre device implantation.
Result:
The LAAC was successfully occluded in the 56 patients. Our data showed no serious residual leak or pericardial effusion occurred during the perioperative period. At a mean follow-up of 37.8 ± 23.5 months, there were 7.1%, 3.6%, and 3.6% rates of death, stroke, and device-related thrombus, respectively. There were no cases of severe residual leak or systemic embolism.
Conclusion:
Taken together, we demonstrate that execution of LAAC with the LAmbre device has high procedural success and prevents AF-related stroke. However, further large-scale trials might be required to confirm our findings.
